drugset / Trial / NCT01461993

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993

Phase 2 Completed 2499 enrolled Pfizer
RandomizedTriple-blindPrevention

Summary

This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine. Healthy male and female subjects will be randomized into 1 of 3 groups; the trial will be an observer-blinded study to the injection being given; and, vaccinated with either Gardasil and rLP2086 concomitantly, rLP2086 and saline concomitantly, or Gardasil and saline concomitantly. The subjects are adolescent children between the ages of 11 and 17 years old.

Timeline

Start
2011-09-28
Primary completion
2013-07-06
Completion
2013-07-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gardasil Vaccine
Comparator rLP2086 Vaccine 120 ug